Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Scientists developed an antibody treatment that...
Cancer
Additional Confirmed Response Reported as Part of Amplia Investor Presentation
HIGHLIGHTS An additional confirmed partial response has been recorded in the ongoing ACCENT trialThis brings the confirmed Objective Response Rate...
Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization
ORLANDO, FL / ACCESS Newswire / December 11, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on...
Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme’s Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually
Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection...
ZEISS celebrates 100 years of advancing innovation in the U.S.
Today, ZEISS marks 100 years of operation in the U.S., helping Americans improve lives and reach profound achievements by applying...
Tivic Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package
Acquisition creates additional near-term revenue opportunities from newly formed Contract Development and Manufacturing Organization (CDMO) subsidiary, Velocity Bioworks™Financing led by...
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY,...
Bionano Recaps Advances in Optical Genome Mapping Showcased at AMP 2025
SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) participated in the Association for Molecular Pathology (AMP)...
MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential
CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- A recent round of open-market purchases marks another display of confidence as the...
ViroMissile Announces First-in-Human Phase I Trial of IDOV-Immune for Advanced Solid Tumors
Study examines the safety and early efficacy of an oncolytic virus via a single intravenous doseSAN DIEGO, Dec. 11, 2025...
Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial
Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden...
Plus Therapeutics Expands CNSide Assay Platform to State of California
CNSide Diagnostics now licensed in 48 U.S. States covering over 90% of the U.S. populationHOUSTON, Dec. 11, 2025 (GLOBE NEWSWIRE)...
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
CLEVELAND, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas...
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose...
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss
CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all...
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025
In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements...
InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China
BEIJING, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that...
DISCO Pharmaceuticals Appoints Mark Manfredi as CEO and Announces Final Close of €36 Million Seed Financing
Mark Manfredi brings over two decades of international biopharmaceutical industry leadership and cancer drug discovery success to DISCO Financing will...
ITM to Present at the 44th Annual J.P. Morgan Healthcare Conference
Garching / Munich, Germany, November 11, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today...
Bio Usawa Welcomes Global Health Strategist, Professor Prashant Yadav, as Chair of Its Global Access and Health Equity Advisory Board
Strategic Appointment Aligns Business Growth with Mission to Deliver Equitable, Affordable MedicinesSAN FRANCISCO and KIGALI, Rwanda, Dec. 11, 2025 (GLOBE...